BILL ANALYSIS

Senate Research Center	S.B. 1887
89R14415 AB-D	By: Sparks
	Health & Human Services
	5/6/2025
	As Filed

AUTHOR'S / SPONSOR'S STATEMENT OF INTENT

During the COVID-19 pandemic, messenger ribonucleic acid (mRNA) vaccines were rushed and widely distributed to prevent further spread of the virus. Concerns were raised about the safety and effectiveness of these immunizations.

Some studies suggest that the mRNA vaccine for COVID-19 is ineffective. Additionally, some studies suggest that mRNA vaccines pose a significant health risk. mRNA vaccines introduce mRNA to cells that utilize the RNA material to produce protein spikes outside of the cell that trigger antibodies. These immunizations utilize lipid nanoparticle complexes which transport mRNA to human cells but, in turn, may also deliver contaminant DNA into human cells. One study found that these vaccines caused a significant increase in myocarditis risk, especially for younger populations. There are also concerns that mRNA vaccines contain toxic components. Polyethylene glycol can cause anaphylaxis and cardiopulmonary distress. mRNA vaccines can also contain arsenic, nickel, and lead. In 2023, Florida's surgeon general called for a halt for all COVID-19 mRNA vaccines due to concerns over the discovery of DNA fragments in every dose of Moderna and Pfizer. This can change normal cells into cancerous ones, affect different parts of the body beyond the injection area, and result in chromosomal instability.

S.B. 1887 amends the current health code and prohibits all immunizations containing mRNA material to persons with the exception of cancer and genetic disorder treatment. This code expires in 2035.

As proposed, S.B. 1887 amends current law relating to the prohibition of immunization with a product containing mRNA material.

RULEMAKING AUTHORITY

This bill does not expressly grant any additional rulemaking authority to a state officer, institution, or agency.

SECTION BY SECTION ANALYSIS

SECTION 1. Amends Subchapter A, Chapter 161, Health and Safety Code, by adding Section 161.0053, as follows:

Sec. 161.0053. PROHIBITED IMMUNIZATION WITH PRODUCT CONTAINING MRNA MATERIAL. (a) Defines "mRNA material."

(b) Prohibits a person from administering for the purpose of immunization a product containing mRNA material.

(c) Provides that this section does not apply to a product containing mRNA material used for the treatment of cancer or a genetic disorder.

(d) Provides that this section expires September 1, 2035.

SECTION 2. Effective date: September 1, 2025.